Alpine Immune Sciences, Inc. announced that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024. Presentation Highlights Include: BAFF- and APRIL-related genes are increased in myeloid and B cells in systemic lupus erythematosus (SLE) patients compared to healthy adults. Povetacicept significantly reduces multiple disease parameters in the NZB/W mouse model of lupus, more effectively than WT TACI-Ig or B cell depletion.

Povetacicept exhibits greater distribution to multiple tissues ? 19-fold higher in the kidney and 3-4-fold higher in the lung, skin, and brain ? in normal mice, compared to WT TACI-Ig, potentially related to advantageous differences in molecular weight, target affinity and/or isoelectric point.